Wirksamkeit von Cannabidiol: Klinische Studien mit Cannabidiol und Cannabidiol-haltigen Extrakten

Abstract

Background: Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prominent active ingredients of the female hemp plant (Cannabis sativa L.). While the combination of THC- and CBD-rich extracts has been established in patients with multiple sclerosis due to their analgesic and antispastic effects, the field of usage of CBD is still at the beginning of its exploration. Methods: By means of a PubMed search and study of the literature found, publications of clinical trials were identified in which aspects of the efficacy of preparations with CBD or CBD-rich extracts as single ingredients were investigated. 25 studies were identified which meet the criteria described. Results and Conclusion: Most selected trials are controlled pilot trials with 20 or fewer patients per group or open trials. There is high evidence for the efficacy of CBD in children with untreatable epilepsy. The number of seizures was significantly reduced in children with Dravet's syndrome at a dosage of 20 mg CBD/kg (in addition to standard therapy). There is also evidence for the efficacy of dosages between 300 and 600 mg for social anxiety disorders. With regard to the antipsychotic effect, the analgesic effect, and the effect on sleep, the results are contradictory.